Terazosin is a quinazoline compound that inhibits α1-adrenergic receptors, exhibiting antihypertensive, anti-metastatic, and anticancer activities. Terazosin is clinically used to treat benign prostatic hyperplasia (BPH) and hypertension. In prostate cells, terazosin increases activation of caspase 3 and induces apoptosis. In prostate cancer cells, this compound induces apoptosis and inhibits cellular proliferation, invasion, and migration.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.